<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00530894</url>
  </required_header>
  <id_info>
    <org_study_id>2006-06-US</org_study_id>
    <nct_id>NCT00530894</nct_id>
  </id_info>
  <brief_title>THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial</brief_title>
  <acronym>PARTNER</acronym>
  <official_title>THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial Edwards SAPIEN Transcatheter Heart Valve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and effectiveness of the device and
      delivery systems (transfemoral and transapical) in high risk, symptomatic patients with
      severe aortic stenosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will undergo a physical exam and screening tests will be performed to determine if
      they are either A) a patient with a high surgical risk or B) not a candidate for surgery.
      They will then be randomized (like the flip of a coin) to have the investigational device
      implanted or to receive the current surgical or medical management available.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2007</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>1 Year</time_frame>
    <description>Death from any cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of Death and Recurrence Hospitalization.</measure>
    <time_frame>duration of study</time_frame>
    <description>Death from any cause or repeat hospitalization after intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional Change of NYHA</measure>
    <time_frame>Baseline to 1 year</time_frame>
    <description>NYHA classification change from baseline to 1 year visit. NYHA provides a way of classifying the extent of heart failure. New York Heart Association (NYHA) is a functional classification of heart failure based on how much a patient is limited during physical activity. The rating ranges from I - IV, with the lowest (I) as no limitations and the highest (IV) unable to carry on any physical activity without discomfort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Major Adverse Cardiac and Cerebro-vascular Events (MACCE)</measure>
    <time_frame>1 year</time_frame>
    <description>Number of participants with MACCE definition includes death, myocardial infarction (MI), stroke and renal failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Hospital Days From the Index Procedure</measure>
    <time_frame>1 year</time_frame>
    <description>Total hospital days from the index procedure or randomization into control arm to one year post procedure or randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life (QOL) From Baseline to 1 Year</measure>
    <time_frame>Baseline and 1 Year</time_frame>
    <description>The QOL questionnaire consisted of: Kansas City Cardiomyopathy (KCCQ), The Medical Outcomes Study Short-Form 12 (SF-12) - physical and metal states.
KCCQ scores are on a range of 0-100, in which 100 reflects the best health status and 0 reflects the worst health status.
SF-12 questionnaire was used in which 100 reflects the best health status and 0 reflects the worst health status.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1057</enrollment>
  <condition>Critical Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort A: Sapien Valve</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cohort A: other surgical valve</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort B: Sapien Valve</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cohort B: Medical therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Edwards SAPIEN Transcatheter Heart Valve</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Surgical Valve Replacement</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>medical management and/or balloon aortic valvuloplasty</intervention_name>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria Cohort A

          1. Patients must have co-morbidities such that the surgeon and cardiologist Co-PIs concur
             that the predicted risk of operative mortality is ≥15% and/or a minimum STS score of
             10

          2. Patient has senile degenerative aortic valve stenosis with echocardiographically
             derived criteria: mean gradient &gt;40 mmHg or jet velocity greater than 4.0 m/s or an
             initial aortic valve area of &lt; 0.8 cm2

          3. Patient is symptomatic from his/her aortic valve stenosis, as demonstrated by NYHA
             Functional Class II or greater

          4. The subject or the subject's legal representative has been informed of the nature of
             the study, agrees to its provisions and has provided written informed consent as
             approved by the IRB of the respective clinical site

          5. The subject and the treating physician agree that the subject will return for all
             required post-procedure follow-up visits

             Cohort B All candidates for Cohort B of this study must meet #2, 3, 4, 5 of the above
             criteria and

          6. The subject, after formal consults by a cardiologist and two cardiovascular surgeons
             agree that medical factors preclude operation, based on a conclusion that the
             probability of death or serious, irreversible morbidity exceeds the probability of
             meaningful improvement. Specifically, the probability of death or serious,
             irreversible morbidity should exceed 50%.

        Exclusion Criteria

          1. Evidence of an acute myocardial infarction ≤ 1month before the intended treatment.

          2. Aortic valve is a congenital unicuspid or bicuspid valve; or is non-calcified

          3. Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant
             aortic regurgitation &gt;3+).

          4. Any therapeutic invasive cardiac procedure performed within 30 days of the index
             procedure, (or 6 months if the procedure was a drug eluting coronary stent
             implantation).

          5. Pre-existing prosthetic heart valve in any position, prosthetic ring, or severe
             (greater than 3+) mitral insufficiency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin B Leon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York-Presbyterian Hospital/Columbia University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Craig Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York-Presbyterian Hospital/Columbia University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scripps Memorial Hospital/Scripps Green Hospital</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Mass General</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic-Saint Marys Hospital</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital of Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnes-Jewish/Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital - Cornell</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical City Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver St. Paul's</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laval Hospital</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Center Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2007</study_first_submitted>
  <study_first_submitted_qc>September 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2007</study_first_posted>
  <results_first_submitted>March 7, 2016</results_first_submitted>
  <results_first_submitted_qc>April 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 11, 2017</results_first_posted>
  <last_update_submitted>August 14, 2017</last_update_submitted>
  <last_update_submitted_qc>August 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Valvular Heart Disease</keyword>
  <keyword>Critical/Severe Aortic Stenosis</keyword>
  <keyword>High risk symptomatic patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>High Risk: TAVR</title>
          <description>Edwards SAPIEN Transcatheter Heart Valve</description>
        </group>
        <group group_id="P2">
          <title>High Risk: SAVR</title>
          <description>Surgical Aortic Valve Replacement</description>
        </group>
        <group group_id="P3">
          <title>Inoperable: TAVR</title>
          <description>Edwards SAPIEN Transcatheter Heart Valve</description>
        </group>
        <group group_id="P4">
          <title>Inoperable: Medical Therapy</title>
          <description>Medical management and/or balloon aortic valvuloplasty</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="348"/>
                <participants group_id="P2" count="351"/>
                <participants group_id="P3" count="179"/>
                <participants group_id="P4" count="179"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="260"/>
                <participants group_id="P2" count="236"/>
                <participants group_id="P3" count="124"/>
                <participants group_id="P4" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="115"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="94"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="89"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Alive and censored prior to 1 year</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The inoperable and high risk groups were not randomized against each other and were essentially two separate trials, therefore the pooled mean and standard deviations do not provide meaningful data and were not reported.</population>
      <group_list>
        <group group_id="B1">
          <title>High Risk: TAVR</title>
          <description>Edwards SAPIEN Transcatheter Heart Valve</description>
        </group>
        <group group_id="B2">
          <title>High Risk: SAVR</title>
          <description>Surgical Valve Replacement</description>
        </group>
        <group group_id="B3">
          <title>Inoperable TAVR</title>
          <description>Edwards SAPIEN Transcatheter Heart Valve</description>
        </group>
        <group group_id="B4">
          <title>Inoperable: Medical Therapy</title>
          <description>Medical management and/or balloon aortic valvuloplasty</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="348"/>
            <count group_id="B2" value="349"/>
            <count group_id="B3" value="179"/>
            <count group_id="B4" value="179"/>
            <count group_id="B5" value="1055"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>High Risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83.61" spread="6.83"/>
                    <measurement group_id="B2" value="84.52" spread="6.37"/>
                    <measurement group_id="B3" value="NA">The inoperable and high risk groups were not randomized against each other and were essentially two separate trials</measurement>
                    <measurement group_id="B4" value="NA">The inoperable and high risk groups were not randomized against each other and were essentially two separate trials</measurement>
                    <measurement group_id="B5" value="84.11" spread="6.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inoperable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">The inoperable and high risk groups were not randomized against each other and were essentially two separate trials</measurement>
                    <measurement group_id="B2" value="NA">The inoperable and high risk groups were not randomized against each other and were essentially two separate trials</measurement>
                    <measurement group_id="B3" value="83.12" spread="8.60"/>
                    <measurement group_id="B4" value="83.18" spread="8.29"/>
                    <measurement group_id="B5" value="83.18" spread="8.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="97"/>
                    <measurement group_id="B4" value="95"/>
                    <measurement group_id="B5" value="490"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="201"/>
                    <measurement group_id="B2" value="198"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="84"/>
                    <measurement group_id="B5" value="565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="324"/>
                    <measurement group_id="B2" value="328"/>
                    <measurement group_id="B3" value="165"/>
                    <measurement group_id="B4" value="162"/>
                    <measurement group_id="B5" value="979"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NYHA Class</title>
          <description>New York Heart Association (NYHA), functional classification of heart failure based on how much a patient is limited during physical activity. The rating ranges from I - IV, with the lowest as no limitations and the highest unable to carry on any physical activity without discomfort.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>High Risk Class II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="NA">The inoperable and high risk groups were not randomized against each other and were essentially two separate trials</measurement>
                    <measurement group_id="B4" value="NA">The inoperable and high risk groups were not randomized against each other and were essentially two separate trials</measurement>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Operable Class II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">The inoperable and high risk groups were not randomized against each other and were essentially two separate trials</measurement>
                    <measurement group_id="B2" value="NA">The inoperable and high risk groups were not randomized against each other and were essentially two separate trials</measurement>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Risk Class III or IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="328"/>
                    <measurement group_id="B2" value="328"/>
                    <measurement group_id="B3" value="NA">The inoperable and high risk groups were not randomized against each other and were essentially two separate trials</measurement>
                    <measurement group_id="B4" value="NA">The inoperable and high risk groups were not randomized against each other and were essentially two separate trials</measurement>
                    <measurement group_id="B5" value="656"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inoperable Class III or IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">The inoperable and high risk groups were not randomized against each other and were essentially two separate trials</measurement>
                    <measurement group_id="B2" value="NA">The inoperable and high risk groups were not randomized against each other and were essentially two separate trials</measurement>
                    <measurement group_id="B3" value="165"/>
                    <measurement group_id="B4" value="168"/>
                    <measurement group_id="B5" value="333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Quality of Life</title>
          <description>The QOL questionnaire consisted of: Kansas City Cardiomyopathy (KCCQ), EuroQOL, SF-12. The QOL questionnaire consisted of: Kansas City Cardiomyopathy (KCCQ), The Medical Outcomes Study Short-Form 12 (SF-12) - physical and metal states. KCCQ scores are on a range of 0-100, in which 100 reflects the best health status and 0 reflects the worst health status. SF-12 questionnaire was used in which 100 reflects the best health status and 0 reflects the worst health status.</description>
          <units>Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>High Risk KCCQ Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.6" spread="21.8"/>
                    <measurement group_id="B2" value="44.5" spread="21.8"/>
                    <measurement group_id="B3" value="NA">The inoperable and high risk groups were not randomized against each other and were essentially two separate trials</measurement>
                    <measurement group_id="B4" value="NA">The inoperable and high risk groups were not randomized against each other and were essentially two separate trials</measurement>
                    <measurement group_id="B5" value="41.88" spread="21.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inoperable KCCQ Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">The inoperable and high risk groups were not randomized against each other and were essentially two separate trials</measurement>
                    <measurement group_id="B2" value="NA">The inoperable and high risk groups were not randomized against each other and were essentially two separate trials</measurement>
                    <measurement group_id="B3" value="36.19" spread="20.52"/>
                    <measurement group_id="B4" value="34.44" spread="20.14"/>
                    <measurement group_id="B5" value="35.35" spread="20.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Risk SF-12 Physical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.6" spread="7.6"/>
                    <measurement group_id="B2" value="30.9" spread="8.2"/>
                    <measurement group_id="B3" value="NA">The inoperable and high risk groups were not randomized against each other and were essentially two separate trials</measurement>
                    <measurement group_id="B4" value="NA">The inoperable and high risk groups were not randomized against each other and were essentially two separate trials</measurement>
                    <measurement group_id="B5" value="30.2" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inoperable SF-12 Physical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">The inoperable and high risk groups were not randomized against each other and were essentially two separate trials</measurement>
                    <measurement group_id="B2" value="NA">The inoperable and high risk groups were not randomized against each other and were essentially two separate trials</measurement>
                    <measurement group_id="B3" value="28.23" spread="7.73"/>
                    <measurement group_id="B4" value="27.70" spread="6.89"/>
                    <measurement group_id="B5" value="28.0" spread="7.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Risk SF-12 Mental</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.9" spread="11.5"/>
                    <measurement group_id="B2" value="47.6" spread="10.7"/>
                    <measurement group_id="B3" value="NA">The inoperable and high risk groups were not randomized against each other and were essentially two separate trials</measurement>
                    <measurement group_id="B4" value="NA">The inoperable and high risk groups were not randomized against each other and were essentially two separate trials</measurement>
                    <measurement group_id="B5" value="47.2" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inoperable SF-12 Mental</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">The inoperable and high risk groups were not randomized against each other and were essentially two separate trials</measurement>
                    <measurement group_id="B2" value="NA">The inoperable and high risk groups were not randomized against each other and were essentially two separate trials</measurement>
                    <measurement group_id="B3" value="44.45" spread="12.16"/>
                    <measurement group_id="B4" value="45.23" spread="11.03"/>
                    <measurement group_id="B5" value="44.84" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>STS Score</title>
          <description>The Society of Thoracic Surgeons (STS) score measures patient risk at the time of cardiovascular surgery on a scale that ranges from 0% to 100%, with higher numbers indicating greater risk.</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>High Risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.8" spread="3.3"/>
                    <measurement group_id="B2" value="11.7" spread="3.5"/>
                    <measurement group_id="B3" value="NA">The inoperable and high risk groups were not randomized against each other and were essentially two separate trials</measurement>
                    <measurement group_id="B4" value="NA">The inoperable and high risk groups were not randomized against each other and were essentially two separate trials</measurement>
                    <measurement group_id="B5" value="11.75" spread="3.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inoperable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">The inoperable and high risk groups were not randomized against each other and were essentially two separate trials</measurement>
                    <measurement group_id="B2" value="NA">The inoperable and high risk groups were not randomized against each other and were essentially two separate trials</measurement>
                    <measurement group_id="B3" value="11.2" spread="5.8"/>
                    <measurement group_id="B4" value="11.9" spread="4.8"/>
                    <measurement group_id="B5" value="11.51" spread="5.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Death</title>
        <description>Death from any cause.</description>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Risk: TAVR</title>
            <description>Edwards SAPIEN Transcatheter Heart Valve</description>
          </group>
          <group group_id="O2">
            <title>High Risk: SAVR</title>
            <description>Surgical Aortic Valve Replacement</description>
          </group>
          <group group_id="O3">
            <title>Inoperable: TAVR</title>
            <description>Edwards SAPIEN Transcatheter Heart Valve</description>
          </group>
          <group group_id="O4">
            <title>Inoperable: Medical Therapy</title>
            <description>Medical management and/or balloon aortic valvuloplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Death</title>
          <description>Death from any cause.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="348"/>
                <count group_id="O2" value="351"/>
                <count group_id="O3" value="179"/>
                <count group_id="O4" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Composite of Death and Recurrence Hospitalization.</title>
        <description>Death from any cause or repeat hospitalization after intervention.</description>
        <time_frame>duration of study</time_frame>
        <population>Composite of Death and recurrence hospitalization was not a primary outcome for the High Risk groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Inoperable: TAVR</title>
            <description>Edwards SAPIEN Transcatheter Heart Valve</description>
          </group>
          <group group_id="O2">
            <title>Inoperable: Medical Therapy</title>
            <description>Medical management and/or balloon aortic valvuloplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Composite of Death and Recurrence Hospitalization.</title>
          <description>Death from any cause or repeat hospitalization after intervention.</description>
          <population>Composite of Death and recurrence hospitalization was not a primary outcome for the High Risk groups.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Change of NYHA</title>
        <description>NYHA classification change from baseline to 1 year visit. NYHA provides a way of classifying the extent of heart failure. New York Heart Association (NYHA) is a functional classification of heart failure based on how much a patient is limited during physical activity. The rating ranges from I - IV, with the lowest (I) as no limitations and the highest (IV) unable to carry on any physical activity without discomfort.</description>
        <time_frame>Baseline to 1 year</time_frame>
        <population>Note that the number of participants analyzed is different from that in the participant flow as there was some missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>High Risk: TAVR</title>
            <description>Edwards SAPIEN Transcatheter Heart Valve</description>
          </group>
          <group group_id="O2">
            <title>High Risk: SAVR</title>
            <description>Surgical Aortic Valve Replacement</description>
          </group>
          <group group_id="O3">
            <title>Inoperable: TAVR</title>
            <description>Edwards SAPIEN Transcatheter Heart Valve</description>
          </group>
          <group group_id="O4">
            <title>Inoperable: Medical Therapy</title>
            <description>Medical management and/or balloon aortic valvuloplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Change of NYHA</title>
          <description>NYHA classification change from baseline to 1 year visit. NYHA provides a way of classifying the extent of heart failure. New York Heart Association (NYHA) is a functional classification of heart failure based on how much a patient is limited during physical activity. The rating ranges from I - IV, with the lowest (I) as no limitations and the highest (IV) unable to carry on any physical activity without discomfort.</description>
          <population>Note that the number of participants analyzed is different from that in the participant flow as there was some missing data.</population>
          <units>Units on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="314"/>
                <count group_id="O3" value="172"/>
                <count group_id="O4" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" lower_limit="2.35" upper_limit="2.65"/>
                    <measurement group_id="O2" value="2.60" lower_limit="2.45" upper_limit="2.76"/>
                    <measurement group_id="O3" value="2.88" lower_limit="2.70" upper_limit="3.07"/>
                    <measurement group_id="O4" value="3.92" lower_limit="3.73" upper_limit="4.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Major Adverse Cardiac and Cerebro-vascular Events (MACCE)</title>
        <description>Number of participants with MACCE definition includes death, myocardial infarction (MI), stroke and renal failure</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Risk: TAVR</title>
            <description>Edwards SAPIEN Transcatheter Heart Valve</description>
          </group>
          <group group_id="O2">
            <title>High Risk: SAVR</title>
            <description>Surgical Aortic Valve Replacement</description>
          </group>
          <group group_id="O3">
            <title>Inoperable: TAVR</title>
            <description>Edwards SAPIEN Transcatheter Heart Valve</description>
          </group>
          <group group_id="O4">
            <title>Inoperable: Medical Therapy</title>
            <description>Medical management and/or balloon aortic valvuloplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Major Adverse Cardiac and Cerebro-vascular Events (MACCE)</title>
          <description>Number of participants with MACCE definition includes death, myocardial infarction (MI), stroke and renal failure</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="348"/>
                <count group_id="O2" value="351"/>
                <count group_id="O3" value="179"/>
                <count group_id="O4" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Hospital Days From the Index Procedure</title>
        <description>Total hospital days from the index procedure or randomization into control arm to one year post procedure or randomization.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Risk: TAVR</title>
            <description>Edwards SAPIEN Transcatheter Heart Valve</description>
          </group>
          <group group_id="O2">
            <title>High Risk: SAVR</title>
            <description>Surgical Aortic Valve Replacement</description>
          </group>
          <group group_id="O3">
            <title>Inoperable: TAVR</title>
            <description>Edwards SAPIEN Transcatheter Heart Valve</description>
          </group>
          <group group_id="O4">
            <title>Inoperable: Medical Therapy</title>
            <description>Medical management and/or balloon aortic valvuloplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Total Hospital Days From the Index Procedure</title>
          <description>Total hospital days from the index procedure or randomization into control arm to one year post procedure or randomization.</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="348"/>
                <count group_id="O2" value="351"/>
                <count group_id="O3" value="179"/>
                <count group_id="O4" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.42" spread="19.05"/>
                    <measurement group_id="O2" value="20.14" spread="23.85"/>
                    <measurement group_id="O3" value="25.24" spread="21.11"/>
                    <measurement group_id="O4" value="17.04" spread="33.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life (QOL) From Baseline to 1 Year</title>
        <description>The QOL questionnaire consisted of: Kansas City Cardiomyopathy (KCCQ), The Medical Outcomes Study Short-Form 12 (SF-12) - physical and metal states.
KCCQ scores are on a range of 0-100, in which 100 reflects the best health status and 0 reflects the worst health status.
SF-12 questionnaire was used in which 100 reflects the best health status and 0 reflects the worst health status.</description>
        <time_frame>Baseline and 1 Year</time_frame>
        <population>Note that the number of participants analyzed is different from that in the participant flow as there was some missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>High Risk: TAVR</title>
            <description>Edwards SAPIEN Transcatheter Heart Valve</description>
          </group>
          <group group_id="O2">
            <title>High Risk: SAVR</title>
            <description>Surgical Aortic Valve Replacement</description>
          </group>
          <group group_id="O3">
            <title>Inoperable: TAVR</title>
            <description>Edwards SAPIEN Transcatheter Heart Valve</description>
          </group>
          <group group_id="O4">
            <title>Inoperable: Medical Therapy</title>
            <description>Medical management and/or balloon aortic valvuloplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life (QOL) From Baseline to 1 Year</title>
          <description>The QOL questionnaire consisted of: Kansas City Cardiomyopathy (KCCQ), The Medical Outcomes Study Short-Form 12 (SF-12) - physical and metal states.
KCCQ scores are on a range of 0-100, in which 100 reflects the best health status and 0 reflects the worst health status.
SF-12 questionnaire was used in which 100 reflects the best health status and 0 reflects the worst health status.</description>
          <population>Note that the number of participants analyzed is different from that in the participant flow as there was some missing data.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="348"/>
                <count group_id="O2" value="351"/>
                <count group_id="O3" value="179"/>
                <count group_id="O4" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>KCCQ Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" spread="22.4"/>
                    <measurement group_id="O2" value="71.1" spread="23.0"/>
                    <measurement group_id="O3" value="69.41" spread="25.37"/>
                    <measurement group_id="O4" value="46.98" spread="24.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12 Physical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3" spread="11.0"/>
                    <measurement group_id="O2" value="36.9" spread="10.4"/>
                    <measurement group_id="O3" value="34.85" spread="11.13"/>
                    <measurement group_id="O4" value="29.68" spread="6.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12 Mental</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.0" spread="10.1"/>
                    <measurement group_id="O2" value="52.9" spread="9.7"/>
                    <measurement group_id="O3" value="53.31" spread="10.00"/>
                    <measurement group_id="O4" value="46.59" spread="11.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 Year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>High Risk: TAVR</title>
          <description>Edwards SAPIEN Transcatheter Heart Valve</description>
        </group>
        <group group_id="E2">
          <title>High Risk: SAVR</title>
          <description>Surgical Aortic Valve Replacement</description>
        </group>
        <group group_id="E3">
          <title>Inoperable: TAVR</title>
          <description>Edwards SAPIEN Transcatheter Heart Valve</description>
        </group>
        <group group_id="E4">
          <title>Inoperable: Medical Therapy</title>
          <description>Medical management and/or balloon aortic valvuloplasty</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="228" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="238" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="134" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="151" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CHF</sub_title>
                <counts group_id="E1" events="73" subjects_affected="50" subjects_at_risk="348"/>
                <counts group_id="E2" events="64" subjects_affected="51" subjects_at_risk="351"/>
                <counts group_id="E3" events="32" subjects_affected="24" subjects_at_risk="179"/>
                <counts group_id="E4" events="102" subjects_affected="78" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="34" subjects_affected="32" subjects_at_risk="348"/>
                <counts group_id="E2" events="44" subjects_affected="38" subjects_at_risk="351"/>
                <counts group_id="E3" events="24" subjects_affected="22" subjects_at_risk="179"/>
                <counts group_id="E4" events="32" subjects_affected="24" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Conduction defects</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="348"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="351"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="179"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="348"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="351"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="179"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Aortic insufficiency without paravalvular leak</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="348"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Valve stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="351"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E4" events="42" subjects_affected="33" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Mitral insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastro-Intestinal Event</sub_title>
                <counts group_id="E1" events="24" subjects_affected="22" subjects_at_risk="348"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="351"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="179"/>
                <counts group_id="E4" events="10" subjects_affected="7" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 1+E21+E16:E40">Other</sub_title>
                <counts group_id="E1" events="127" subjects_affected="91" subjects_at_risk="348"/>
                <counts group_id="E2" events="129" subjects_affected="86" subjects_at_risk="351"/>
                <counts group_id="E3" events="98" subjects_affected="60" subjects_at_risk="179"/>
                <counts group_id="E4" events="105" subjects_affected="68" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Device embolization</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Device migration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Perivalvular leak</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (including Endocarditis)</sub_title>
                <counts group_id="E1" events="96" subjects_affected="70" subjects_at_risk="348"/>
                <counts group_id="E2" events="74" subjects_affected="59" subjects_at_risk="351"/>
                <counts group_id="E3" events="53" subjects_affected="35" subjects_at_risk="179"/>
                <counts group_id="E4" events="38" subjects_affected="30" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Perforation or damage to myocardium</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="348"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Access site nerve injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Abnormal Lab Values</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="348"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="351"/>
                <counts group_id="E3" events="17" subjects_affected="12" subjects_at_risk="179"/>
                <counts group_id="E4" events="17" subjects_affected="11" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Electrolyte Imbalance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="STS/AATS">Neurological event (including TIA stroke and psychomotor deficit)</sub_title>
                <counts group_id="E1" events="33" subjects_affected="33" subjects_at_risk="348"/>
                <counts group_id="E2" events="28" subjects_affected="24" subjects_at_risk="351"/>
                <counts group_id="E3" events="28" subjects_affected="24" subjects_at_risk="179"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="348"/>
                <counts group_id="E2" events="29" subjects_affected="26" subjects_at_risk="351"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="179"/>
                <counts group_id="E4" events="12" subjects_affected="12" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Renal insufficiency</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="348"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="351"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Event</sub_title>
                <counts group_id="E1" events="66" subjects_affected="46" subjects_at_risk="348"/>
                <counts group_id="E2" events="76" subjects_affected="61" subjects_at_risk="351"/>
                <counts group_id="E3" events="28" subjects_affected="25" subjects_at_risk="179"/>
                <counts group_id="E4" events="23" subjects_affected="21" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="348"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="351"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="179"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title vocab="STS/FDA">Bleeding event</sub_title>
                <counts group_id="E1" events="33" subjects_affected="32" subjects_at_risk="348"/>
                <counts group_id="E2" events="42" subjects_affected="38" subjects_at_risk="351"/>
                <counts group_id="E3" events="26" subjects_affected="23" subjects_at_risk="179"/>
                <counts group_id="E4" events="14" subjects_affected="13" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Hemorrhagic/Vascular event</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="348"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="351"/>
                <counts group_id="E3" events="24" subjects_affected="23" subjects_at_risk="179"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="348"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="351"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="179"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="348"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="351"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Ischemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="348"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="351"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>MI</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="348"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="351"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="179"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="348"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="351"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Thromboembolism</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="348"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="351"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="179"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="179"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="230" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="217" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="140" subjects_at_risk="179"/>
                <counts group_id="E4" subjects_affected="103" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="49" subjects_affected="43" subjects_at_risk="348"/>
                <counts group_id="E2" events="88" subjects_affected="78" subjects_at_risk="351"/>
                <counts group_id="E3" events="30" subjects_affected="26" subjects_at_risk="179"/>
                <counts group_id="E4" events="18" subjects_affected="16" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>CHF</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="348"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="351"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="179"/>
                <counts group_id="E4" events="17" subjects_affected="15" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Valve stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastro-Intestinal Event</sub_title>
                <counts group_id="E1" events="29" subjects_affected="22" subjects_at_risk="348"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="351"/>
                <counts group_id="E3" events="18" subjects_affected="13" subjects_at_risk="179"/>
                <counts group_id="E4" events="9" subjects_affected="7" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="242" subjects_affected="133" subjects_at_risk="348"/>
                <counts group_id="E2" events="219" subjects_affected="124" subjects_at_risk="351"/>
                <counts group_id="E3" events="204" subjects_affected="87" subjects_at_risk="179"/>
                <counts group_id="E4" events="80" subjects_affected="44" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (including Endocarditis)</sub_title>
                <counts group_id="E1" events="80" subjects_affected="60" subjects_at_risk="348"/>
                <counts group_id="E2" events="69" subjects_affected="58" subjects_at_risk="351"/>
                <counts group_id="E3" events="57" subjects_affected="44" subjects_at_risk="179"/>
                <counts group_id="E4" events="52" subjects_affected="34" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Abnormal Lab Values</sub_title>
                <counts group_id="E1" events="128" subjects_affected="84" subjects_at_risk="348"/>
                <counts group_id="E2" events="136" subjects_affected="84" subjects_at_risk="351"/>
                <counts group_id="E3" events="86" subjects_affected="51" subjects_at_risk="179"/>
                <counts group_id="E4" events="46" subjects_affected="28" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological event (including TIA stroke and psychomotor deficit)</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="179"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="179"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Event</sub_title>
                <counts group_id="E1" events="38" subjects_affected="33" subjects_at_risk="348"/>
                <counts group_id="E2" events="35" subjects_affected="32" subjects_at_risk="351"/>
                <counts group_id="E3" events="18" subjects_affected="15" subjects_at_risk="179"/>
                <counts group_id="E4" events="12" subjects_affected="10" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="25" subjects_affected="24" subjects_at_risk="348"/>
                <counts group_id="E2" events="52" subjects_affected="47" subjects_at_risk="351"/>
                <counts group_id="E3" events="17" subjects_affected="15" subjects_at_risk="179"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding event</sub_title>
                <counts group_id="E1" events="27" subjects_affected="25" subjects_at_risk="348"/>
                <counts group_id="E2" events="25" subjects_affected="22" subjects_at_risk="351"/>
                <counts group_id="E3" events="21" subjects_affected="16" subjects_at_risk="179"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Hemorrhagic/Vascular event</sub_title>
                <counts group_id="E1" events="26" subjects_affected="25" subjects_at_risk="348"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="351"/>
                <counts group_id="E3" events="25" subjects_affected="20" subjects_at_risk="179"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="348"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="351"/>
                <counts group_id="E3" events="22" subjects_affected="19" subjects_at_risk="179"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="348"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="351"/>
                <counts group_id="E3" events="28" subjects_affected="24" subjects_at_risk="179"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="179"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Site cannot publish or present on overall study results not yet published. PI may publish his own clinical study data subject to EW review prior submission or presentation, but data analyses of site-specific results can occur only in intervals as specified in the CSA.
Publication of site-specific results cannot include claims of device safety and effectiveness and requires EW review.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tenley Koepnick</name_or_title>
      <organization>Edwards Lifesciences</organization>
      <phone>949-250-6504</phone>
      <email>tenley_koepnick@edwards.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

